1
James Doherty
Clifton John Blankley, Annette Marian Doherty, James Marino Hamby, Robert Lee Panek, Mel Conrad Schroeder, Howard Daniel Hollis Showalter, Cleo Connolly: 6-Aryl pyrido�2,3-d! pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation. Charles W Ashbrook, March 31, 1998: US05733913 (64 worldwide citation)

6-Aryl pyrido�2,3-d!pyrimidines and naphthyridines are inhibitors of protein tyrosine kinase, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating atherosclerosis, restenosis, psoriasis, as well as bacterial infections.


2

3
James Doherty
Clifton John Blankley, Diane Harris Boschelli, Annette Marian Doherty, James Marino Hamby, Sylvester Klutchko, Robert Lee Panek: Pyrido�2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, March 31, 1998: US05733914 (48 worldwide citation)

6-Aryl pyrido�2,3-d!pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.


4
James Doherty
Clifton J Blankley, Diane H Boschelli, Annette M Doherty, James M Hamby, Sylvester Klutchko, Robert L Panek: Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation. Warner Lambert Company, Charles W Ashbrook, April 15, 1997: US05620981 (42 worldwide citation)

6-Aryl pyrido[2,3-d]pyrimidine 7-imines, 7-ones, and 7-thiones are inhibitors of protein tyrosine kinases, and are thus useful in treating cellular proliferation mediated thereby. The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.


5
Nelson H Ludwig, Earl E Ose: Controlled release formulations and method of treatment. Eli Lilly and Company, Charles W Ashbrook, Arthur R Whale, October 6, 1981: US04293539 (146 worldwide citation)

Controlled release formulations useful in the prolonged treatment and control of microbial infections in animals are comprised of a microbial agent intimately dispersed throughout a copolymer derived from lactic acid and glycolic acid. A method for providing protection to animals for extended period ...


6
Robert S Nevin: Polymerization process and product. Eli Lilly and Company, Charles W Ashbrook, Arthur R Whale, June 16, 1981: US04273920 (108 worldwide citation)

Lactic-glycolic copolymers having molecular weights of about 6000 to about 35000 are prepared by condensation of lactic acid and glycolic acid in the presence of readily removable strong acid ion-exchange resins.


7
Bryan B Molloy, Klaus K Schmiegel: Treatment of obesity with aryloxyphenylpropylamines. Eli Lilly and Company, Charles W Ashbrook, December 2, 1986: US04626549 (96 worldwide citation)

3-Aryloxy-3-phenylpropylamines and acid addition salts thereof are useful in blocking uptake of monoamines by brain neurons, and are thus effective in treating disorders of sleep, sexual performance, appetite, muscular function, and pituitary function.


8
Susan M Bjorge, Ann E Black, Bruce D Roth, Thomas Woolf: [(Hydroxyphenylamino) carbonyl] pyrroles. Warner Lambert Company, Charles W Ashbrook, January 31, 1995: US05385929 (85 worldwide citation)

2-(4-Fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[( hydroxyphenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, and their lactone forms, and salts and solyates thereof, inhibit cholesterol biosynthesis, and thus are useful in treating hypercholesterolemia.


9
Alexander J Bridges, Alan R Saltiel: 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders. Warner Lambert Company, Charles W Ashbrook, June 11, 1996: US05525625 (74 worldwide citation)

2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran inhibits MEK and, as such, is effective in treating cancer and other proliferative diseases such as psoriasis and restenosis.


10
Randall Wayne Whitcomb: Combinations for diabetes. Warner Lambert Company, Charles W Ashbrook, January 4, 2000: US06011049 (70 worldwide citation)

Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.